Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Axial Spondyloarthritis With a History of Anterior Uveitis
NCT03020992Phase 4Completed
- Sponsor
- UCB
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 5
01
Overview
A Phase 4 trial of certolizumab pegol in axial spondyloarthritis (axSpA), anterior uveitis (AU), sponsored by UCB. Started Dec 2016; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)anterior uveitis (AU)
Beyond the preview
Go deeper on NCT03020992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020992.